Aditxt (ADTX) shares were up over 57% in recent Tuesday trading after its acquisition target, Appili Therapeutics, submitted four new federal funding proposals totaling $117.5 million.

The largest funding proposal seeks $46.3 million to develop a vaccine against invasive fungal infections from the National Institute of Allergy and Infectious Diseases, Appili said.

Aditxt subsidiary, Adivir, is in the process of acquiring Appili, with the transaction expected to close in Q1, the company said.

Trading volume stood at over 87 million shares against a daily average of about 376,000.

Price: 6.90, Change: +2.53, Percent Change: +57.89